Anthem Biosciences Makes Strong Market Debut Today: List at 27% Premium

Anthem Biosciences, a Bengaluru-headquartered contract research, development and manufacturing organisation (CRDMO), experienced a blockbuster debut on bourses today. 

From the issue price of ₹570, the shares listed at ₹723.05 on NSE and ₹723.10 on NSE, a 27% premium. 

The ₹3,395‑crore offer, entirely an offer for sale by existing shareholders, attracted overwhelming interest from all investor categories, receiving a total subscription of 63.86 times. 

Qualified Institutional Buyers (QIBs) took the lead by subscribing 182.65x, followed by Non-Institutional Investors 42.36x, Retail Individual Investors (RIIs) 5.64x, and Employees 6.60x

The company will not receive any proceeds from the issue, as it’s pure OFS, and the proceeds will directly go to the selling shareholders. 

Anthem Biosciences is a contract research, development, and manufacturing organisation (CRDMO). The company offers fully integrated services across the pharmaceutical value chain, from early-stage drug discovery to large-scale commercial manufacturing. 

They cater to a broad spectrum of global clients, from emerging biotech firms to established multinational pharmaceutical companies. Anthem’s revenue from operations grew by 34.29%, reaching ₹1,844.55 crore in fiscal 2025, up from ₹1,419.37 crore in fiscal 2024.